Through unbiased phenotypic screening using cancer growth inhibition as a functional readout, we selected 2 biparatopic antibody candidates that achieved highest efficacy in vitro and confirmed their therapeutic activities in FGFR2 fusion ICC xenograft models in vivo. This evidence concerns the gene FGFR2 and intrahepatic cholangiocarcinoma.